Research grants summary
Grants as Principal Investigators: 2013-2023
Hovedinnhold
Detailed Grants are found in the differents projects descriptions and their included links. This is a summary for the grants to the group in the last 10 years.
Public Funding
Grant ID | Granting body-Organization | Project | Amount (M.NOK) | Funding Period | Principal Investigator |
Helse Vest (Strategic funding grant) | 20 | 2020 – 2024 | |||
341675 | verifikasjonsmidler fra NFR | The Next Generation Kidney Function test | 5 | 2023-2026 | |
HV912167 | Helse Vest | Targeting Epithelial-to-Mesenchymal Transition to Treat Advanced Renal Cell Carcinoma: From Mice to Men!» | 3.855 | 2017-2020 | |
HV912233 | Helse Vest | Targeting Renal Fibrosis: From Man to Zebrafish and Back to Man! | 4.433 | 2018-2021 | |
F-12559 | Helse Vest (Strategic funding grant) | Digital technology for personalised management and therapy of hypertensive nephropathy | 20 | 2020-2024 | |
334097 | Research Council of Norway | Single Cell Data-derived European Study for Personalised Management of Chronic Kidney Disease (CKD) in Children and Adolescents (Personalized management of MCD) | 12 | 2023-2028 |
Industry Funds
Grant ID | Granting body-Organization | Project | Amount (M.NOK) | Funding Period | Principal Investigator |
Alexion | Alexion Pharma Nordics AB NUF | Investigation of Complement System Activation in kidney diseases | 0.3 | 2016-2019 | |
Amicus | Amicus Therapeutics UK Limited | Effects of Migalastat in Fabry Nephropathy assessed by RNA sequencing of Kidney Biopsies | USD 66K | 2017-2020 | H.P. Marti |
Genzyme | Sanofi Aventis (Genzyme) Norge | Fabry Nephropathy: Improved Therapy by Directed Drug Delivery | 0.64 | 2014-2016 | H.P. Marti |
GZ-2013-11021 | Sanofi-Genzyme | Improved Diagnosis and Therapy of Fabry Nephropathy by Biomarkers and by Novel Therapeutic Targets | Euro 280K | 2014-2021 | H.P. Marti |
IIR NOR-00380 | Takeda-Shire | Systems Medicine and Definition of Novel Drug Combination Therapy in Fabry Nephropathy | Euro 453.330 | 2015-2021 | H.P. Marti |
LS#37579 | Alexion Pharmaceuticals | Investigation of Complement System Activation in Patients with IgA Nephropathy | Euro 99.750 | 2020-2024 | H.P. Marti |
